Blood-incompatibility or haemo-incompatibility is an inevitability of all blood-contacting device applications and therapies, including haemodialysis. While anticoagulation successfully prevents clotting within the extracorporeal circuit to allow removal of uraemic toxins across the dialysis membrane wall, it is far from ideal, triggering side effects in some instances.
This activation results in increased adsorption of proteins on the membrane surface. The buildup of this secondary membrane layer impairs the transport properties of the membrane to reduce the clearance of uraemic toxins. This is also accompanied by the activation of complement system-dependent immune response pathways which leads to alterations in various blood cells, contributing to thrombotic processes and a procoagulant state. Complement activation also promotes recruitment and activation of leukocytes resulting in oxidative burst and release of pro-inflammatory cytokines and chemokines, thereby worsening the elevated underlying inflammation and oxidative stress condition of chronic kidney disease patients.
In this webinar, the interactions of the membrane with the blood will be discussed in detail, looking from both the mechanistic involved and clinical outcomes associated with incompatibility.
Event Date: 9/13/2022